{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:15:30Z","timestamp":1791908130514,"version":"4.3.4"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T00:00:00Z","timestamp":1390953600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0087488","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T21:54:30Z","timestamp":1391032470000},"page":"e87488","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":97,"title":["Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease"],"prefix":"10.1371","volume":"9","author":[{"given":"Christine","family":"Bernsmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Meyer-Gerspach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea S.","family":"Blaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Jeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Steinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus H.","family":"Heim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Beglinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,1,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Yilmaz Y (2012) Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther. doi:10.1111\/apt.12046.","DOI":"10.1111\/apt.12046"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","article-title":"A position statement on NAFLD\/NASH based on the EASL 2009 special conference","volume":"53","author":"V Ratziu","year":"2010","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"N Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"H Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmed.2007.12.003","article-title":"Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis","volume":"14","author":"F Marra","year":"2008","journal-title":"Trends Mol Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0167-0115(03)00111-3","article-title":"Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects","volume":"114","author":"T Vilsb\u00f8ll","year":"2003","journal-title":"Regul Pept"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The Physiology of Glucagon-Like Peptide 1","volume":"87","author":"JJ Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"ref8","first-page":"4382","article-title":"A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7\u201336) Amide on Ad Libitum Energy Intake in Humans","volume":"86","author":"C Verdich","year":"2001","journal-title":"JCEM"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials","volume":"344","author":"T Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"Drucker DJ, Nauck MA (11) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","journal-title":"The Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"X Ding","year":"2006","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"NA Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"G225","DOI":"10.1152\/ajpgi.00274.2011","article-title":"Glp-1 Analog, Liraglutide, Ameliorates Hepatic Steatosis and Cardiac Hypertrophy in C57BL\/6J Mice Fed a Western Diet","volume":"302","author":"JE Mells","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/liv.12120","article-title":"GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK","volume":"33","author":"L Zhang","year":"2013","journal-title":"Liver Int"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.regpep.2011.04.006","article-title":"GLP-1-derived nonapeptide GLP-1(28\u201336)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice","volume":"169","author":"E Tomas","year":"2011","journal-title":"Regulatory Peptides"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"G762","DOI":"10.1152\/ajpgi.00476.2011","article-title":"Glucagon-Like Peptide-1 Receptor Agonism Improves Metabolic, Biochemical, and Histopathological Indices of Nonalcoholic Steatohepatitis in Mice","volume":"302","author":"JL Trevaskis","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"G Svegliati-Baroni","year":"2011","journal-title":"Liver International"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"S Ben-Shlomo","year":"2011","journal-title":"Journal of Hepatology"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e25269","DOI":"10.1371\/journal.pone.0025269","article-title":"GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy","volume":"6","author":"S Sharma","year":"2011","journal-title":"PLoS ONE"},{"key":"ref20","first-page":"729","article-title":"Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism","volume":"5","author":"M Miyazaki","year":"2012","journal-title":"Mol Med Report"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e50117","DOI":"10.1371\/journal.pone.0050117","article-title":"Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists","volume":"7","author":"DJ Cuthbertson","year":"2012","journal-title":"PLoS ONE"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"DE Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","article-title":"Correct homeostasis model assessment (HOMA) evaluation uses the computer program","volume":"21","author":"JC Levy","year":"1998","journal-title":"Diabetes Care"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/clpt.2009.159","article-title":"Orally Administered Glucagon-Like Peptide-1 Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects","volume":"86","author":"RE Steinert","year":"2009","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"MB Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients","volume":"50","author":"T Vilsb\u00f8ll","year":"2001","journal-title":"Diabetes"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2337\/db07-1124","article-title":"Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance","volume":"57","author":"K Vollmer","year":"2008","journal-title":"Diabetes"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/jc.2010-2435","article-title":"Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes","volume":"96","author":"JI Bagger","year":"2011","journal-title":"JCEM"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1517\/14728220903241633","article-title":"Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors","volume":"18","author":"M Rizzo","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.2337\/diacare.24.9.1640","article-title":"Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men","volume":"24","author":"E Rask","year":"2001","journal-title":"Diabetes Care"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00125-007-0899-2","article-title":"Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and\/or impaired glucose tolerance in the EUGENE2 study","volume":"51","author":"M Laakso","year":"2008","journal-title":"Diabetologia"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0196-9781(02)00087-6","article-title":"Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men","volume":"23","author":"C Feinle","year":"2002","journal-title":"Peptides"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2006.10.025","article-title":"Gastric Sensorimotor Functions and Hormone Profile in Normal Weight, Overweight, and Obese People","volume":"131","author":"MI Vazquez Roque","year":"2006","journal-title":"Gastroenterology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"E294","DOI":"10.1152\/ajpendo.00533.2012","article-title":"Gastric emptying, mouth-to-cecum transit, and glycemic, insulin, incretin, and energy intake responses to a mixed-nutrient liquid in lean, overweight, and obese males","volume":"304","author":"RV Seimon","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/ajcn\/69.5.999","article-title":"Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility","volume":"69","author":"CG MacIntosh","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1210\/jc.2011-2583","article-title":"Comparative Effects of Variations in Duodenal Glucose Load on Glycemic, Insulinemic, and Incretin Responses in Healthy Young and Older Subjects","volume":"97","author":"LG Trahair","year":"2012","journal-title":"JCEM"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e003995","DOI":"10.1136\/bmjopen-2013-003995","article-title":"Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial","volume":"3","author":"MJ Armstrong","year":"2013","journal-title":"BMJ Open"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","article-title":"Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms","volume":"48","author":"E Bugianesi","year":"2005","journal-title":"Diabetologia"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI60016","article-title":"Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover","volume":"122","author":"RH Unger","year":"2012","journal-title":"J Clin Invest"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diabetes.48.5.1198","article-title":"Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo","volume":"48","author":"AD Cherrington","year":"1999","journal-title":"Diabetes"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diab.42.11.1663","article-title":"Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function","volume":"42","author":"SE Kahn","year":"1993","journal-title":"Diabetes"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1172\/JCI10761","article-title":"Interactions between insulin resistance and insulin secretion in the development of glucose intolerance","volume":"106","author":"MK Cavaghan","year":"2000","journal-title":"J Clin Invest"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0087488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T20:46:10Z","timestamp":1597437970000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0087488"}},"subtitle":[],"editor":[{"given":"Salvatore","family":"Petta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,29]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0087488","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,29]]}}}